|
市場調査レポート
商品コード
1379033
デジタル治療薬市場レポート:用途、最終用途、地域別、2023-2028年Digital Therapeutics Market Report by Application (Diabetes, Obesity, CVD, CNS Disease, Respiratory Diseases, Smoking Cessation, and Others), End Use (Patients, Providers, Payers, Employers, and Others), and Region 2023-2028 |
||||||
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。 |
デジタル治療薬市場レポート:用途、最終用途、地域別、2023-2028年 |
出版日: 2023年11月02日
発行: IMARC
ページ情報: 英文 144 Pages
納期: 2~3営業日
|
世界のデジタル治療薬市場規模は2022年に50億米ドルに達しました。今後、IMARC Groupは、市場は2028年までに150億米ドルに達し、2022年から2028年の間に20.1%の成長率(CAGR)を示すと予測しています。デジタル行動モニタリング治療に対する需要の高まり、慢性疾患の有病率の増加、個人の健康とフィットネスに対する大衆の意識の高まりは、市場を牽引する重要な要因の一つです。
スマートフォンとタブレットの利用増加が市場成長を促進
スマートフォンやタブレットへの依存度の高まりは、さまざまなヘルスケアアプリと相まって、デジタル治療薬市場の成長を促進しています。スマートフォンやタブレットベースのヘルスケアアプリには、投薬ミスの発生率の低下、予防医療の促進、より正確な人員配置など、数多くの利点があります。ヘルスケアにおける個人用技術機器の利用の増加は、デジタル治療薬(DTx)治療の需要を刺激しています。DTxは、治療法の安全性と有効性に対する患者のアクセスを向上させ、さまざまな言語で情報を提示し、病気や治療法に関する関連情報を提供し、医師が患者をケアする能力を拡大しています。さらに、DTxは先進的なケア提供方法であり、自宅で簡単に実施でき、従来の治療法に伴うスティグマ(烙印)を排除することができます。
市場構造、主要企業による市場シェア、主要企業のポジショニング、主要成功戦略、競合ダッシュボード、企業評価象限などの競合分析が網羅されています。また、主要企業の詳細プロファイルも掲載しています。市場構造は中程度に細分化されており、多数の世界的・地域的プレーヤーが存在しています。さらに、研究開発(R&D)の革新や合併・買収(M&A)の増加により、この市場の競合環境は激化しています。デジタル治療薬業界では、市場構造が細分化されており、製品の差別化やスイッチングコストが低いため、新規参入の動きは緩やかです。また、mヘルス開発者の増加が新規参入業者の脅威を高めています。しかし、特許の要件と先端技術の高コスト、厳格な規制手続きにより、新規参入業者の脅威は減少しています。
デジタル治療薬とは?
デジタル治療薬(DTx)とは、医療上の障害や疾患を予防、管理、治療するための、高品質なソフトウェア・プログラムによるエビデンスに基づく治療介入です。DTxはSoftware-as-a-medical device(SaMD)の一種であり、ソフトウェアによる介入によって患者に行動変容をもたらし、病態の治療に役立てるものです。DTxは、単独で、あるいは治療の最適化のためにソフトウェアを利用して病気を治療する、急速に出現しつつある治療法の一種です。DTxは、2型糖尿病、うっ血性心不全、肥満、アルツハイマー病、認知症、喘息、薬物乱用、注意欠陥多動性障害(ADHD)、高血圧、不安、うつ病など、さまざまな疾患や症状の予防と管理を支援します。DTxはまた、患者の服薬アドヒアランスを向上させ、ヘルスケア専門家(HCP)が患者やビジネスをデジタル管理できるよう支援します。
COVID-19パンデミックの到来は、ヘルスケア業界にとっての分水嶺と言えます。医療提供のあり方を劇的に変化させるとともに、世界の医療緊急事態に適切に対処するための世界各国の政府の準備不足を露呈しました。第一線の医療従事者はCOVID-19患者の管理に携わったが、他の健康状態、特に慢性的な健康状態にある患者は、診療所での受診が延期されたり回避されたりして困難を経験しました。さらに、併存疾患、特に肥満、心臓合併症、糖尿病を持つ患者のCOVID-19の転帰は、そうでない患者よりも悪かったため、これらの患者はさらに警戒するよう求められました。パンデミックはまた、うつ病、不安障害、離脱症状などの精神疾患ももたらし、その管理は対面診療の欠如のために困難でした。このような相互に関連した出来事により、ヘルスケア提供者は、健康危機に対処するためのデジタルヘルス・ソリューションに注目するようになっています。COVID-19の大流行時には、デジタルヘルス技術の導入に関してポジティブな傾向が観察され、医療業務とサービス提供の効率と有効性が向上しました。パンデミックが始まった後、様々な分野でのDTxアプリケーションの採用が何倍にも加速しました。さらに、情勢の大流行は、患者エンゲージメントを変革し、ヘルスケア全体のデータを統合することで、バーチャルケア技術や在宅ケア技術の採用を増加させました。
現在、2型糖尿病患者の間で、病気を管理し、モノのインターネット(IoT)対応のインスリンポンプやその他の健康モニタリングシステムを使用できるようにするためのDTxに対する需要が増加しています。このことは、服薬アドヒアランスと健康的なライフスタイルの変化を確実にするためのデジタル行動モニタリング治療に対する需要の増加とともに、市場の成長を支える重要な要因の1つとなっています。さらに、従来の治療と比較して、経過観察の必要性や再発を減らすためにDTxの利用が増加していることも、良好な市場見通しをもたらしています。さらに、心臓病、脳卒中、がん、肥満、関節炎などの慢性疾患の有病率が増加しています。これは、個人の健康とフィットネスに対する大衆の意識の高まりと相まって、市場の成長を促進しています。さらに、医師が患者の服薬アドヒアランスを管理し、支払者、医療提供者、薬局などの利害関係者間でシームレスなデータ転送を可能にする統合ヘルスエコシステムを構築するためのDTxに対する需要の高まりが、市場の成長を後押ししています。
The global digital therapeutics market size reached US$ 5.0 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 15.0 Billion by 2028, exhibiting a growth rate (CAGR) of 20.1% during 2022-2028. The growing demand for digital behavior-monitoring treatment, increasing prevalence of chronic diseases, and rising awareness among the masses about personal health and fitness represent one of the key factors driving the market.
Increasing Usage of Smartphones and Tablets Propelling Market Growth
The rising reliance on smartphones and tablets, coupled with different healthcare apps, is propelling the growth of the digital therapeutics market. Smartphones and tablet-based healthcare apps have numerous advantages over the lower rate of medication errors, facilitating preventive care, and more accurate staffing. The increasing utilization of personal technological devices in healthcare is catalyzing the demand for digital therapeutics (DTx) treatments. DTx is enhancing patient access to the safety and effectiveness of treatments, presenting information in different languages, providing relevant information about diseases and treatments, and expanding the ability of physicians to care for patients. Furthermore, it is an advanced mode of care delivery, which can be easily implemented at home and eliminates any stigma associated with traditional therapies.
Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. The market structure is moderately fragmented with the presence of a large number of global and regional players. Moreover, the competitive environment in this market is intensifying due to the increasing number of research and development (R&D) innovations and mergers and acquisitions (M&A). The volume of new entrants is moderate in the digital therapeutics industry due to the fragmented market structure and low product differentiation and switching cost. In addition, the growing number of mhealth developers is contributing to the high threat of new entrants. However, the requirement of patents and high costs of advanced technologies along with stringent regulatory procedures, decreases the threat from new entrants.
What are Digital Therapeutics?
Digital therapeutics (DTx) is an evidence-based therapeutic intervention driven by high-quality software programs to prevent, manage, or treat a medical disorder or disease. It is a form of a software-as-a-medical device (SaMD) that relies on software interventions to bring about behavioral changes in patients and help treat their conditions. DTx is a fast-emerging class of therapies that utilizes software to treat disease as a standalone or for treatment optimization. It assists in preventing and managing a wide variety of diseases and conditions, such as type 2 diabetes, congestive heart failure, obesity, Alzheimer's disease, dementia, asthma, substance abuse, attention deficit hyperactivity disorder (ADHD), hypertension, anxiety, depression, and several others. DTx also aids in improving patient medication adherence and supporting healthcare professionals (HCPs) to manage their patients and businesses digitally.
The arrival of the COVID-19 pandemic can be described as a watershed moment for the healthcare industry. It changed the manner of healthcare delivery dramatically while exposing the lack of preparedness on the part of governments worldwide to adequately tackle a global healthcare emergency. Frontline health workers were involved in managing COVID-19 patients, but patients with other health conditions, especially chronic health conditions, experienced difficulties as their in-clinic visits were postponed or avoided. Moreover, as the outcomes of COVID-19 among patients with comorbidities, especially obesity, heart complications, and diabetes, were worse than those without, these patients were asked to be additionally vigilant. The pandemic also brought a fair share of mental health disorders, including depression, anxiety, and withdrawals, and their management was a challenge due to the lack of face-to-face visits. These interconnected events have made healthcare providers look out for digital health solutions to tackle health crisis. There was a positive trend observed during the COVID-19 outbreak in relation to the adoption of digital health technologies, which increased the efficiency and effectiveness of healthcare operations and service delivery. After the pandemic started, the adoption of DTx applications in various fields accelerated many folds. Additionally, the COVID-19 pandemic increased the adoption of virtual and home care technologies by transforming patient engagement and integrating data across the healthcare landscape.
At present, there is a rise in the demand for DTx among type 2 diabetes patients to manage the disease and enable them to use the internet of things (IoT)-enabled insulin pumps and other health monitoring systems. This, along with the increasing demand for digital behavior-monitoring treatment to ensure medication adherence and healthy lifestyle changes, represents one of the key factors supporting the growth of the market. In addition, the growing utilization of DTx to reduce the need for more follow-up checkups and relapses compared to traditional treatments is offering a favorable market outlook. Moreover, there is an increase in the prevalence of chronic diseases, such as heart disease, stroke, cancer, obesity, and arthritis. This, coupled with the rising awareness among the masses about personal health and fitness, is propelling the growth of the market. Additionally, the escalating demand for DTx to help doctors manage patient adherence to medical regimens and build an integrated health ecosystem that can enable the seamless transfer of data between different stakeholders, such as payers, providers, and pharmacies, is bolstering the growth of the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global digital therapeutics market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on application and end use.
Diabetes
Obesity
CVD
CNS Disease
Respiratory Diseases
Smoking Cessation
Others
The report has provided a detailed breakup and analysis of the digital therapeutics market based on the application. This includes diabetes, obesity, CVD, CNS disease, respiratory diseases, smoking cessation, and others. According to the report, diabetes represented the largest segment due to the rising prevalence of diabetes, along with the high risk of associated conditions, such as cardiac arrests, kidney failure, and blindness, in diabetic patients. Moreover, the growing integration of DTx with numerous medical devices, such as insulin pumps, glucose blood meters, and wearable gadgets, is positively influencing the market.
Patients
Providers
Payers
Employers
Others
A detailed breakup and analysis of the digital therapeutics market based on the end use has also been provided in the report. This includes patients, providers, payers, employers, and others. According to the report, patients accounted for the largest market share due to the rising adoption of DTx among patients for numerous associated benefits pertaining to elective health management at an affordable cost. In addition, the increasing consumer inclination towards patient management systems for improving retention and compliance with post hospitalization follow-up visits is catalyzing the demand for DTx.
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America (the United States and Canada) was the largest market for digital therapeutics. Some of the factors driving the North America digital therapeutics market included the growing geriatric population, continuous upgradations in drug approval processes by the Food and Drug Administration (FDA), rising awareness about the benefits of DTx, etc. In addition, the growing utilization of DTx as a standalone therapy or in conjunction with medications, devices, and other therapies to optimize patient care and healthcare outcomes is offering a favorable market outlook.
2Morrow Inc.
Canary Health Inc.
Click Therapeutics Inc.
Mango Health Inc. (TrialCard Incorporated)
Noom Health Inc.
Omada Health Inc.
Pear Therapeutics, Inc.
Propeller Health (ResMed)
Teladoc Health Inc.
Voluntis Inc.
WellDoc Inc.
Please note that this only represents a partial list of companies, and the complete list has been provided in the report.